MedTrace Logo

Trial in Patients With Relapsed Ovarian Cancer

NCT03267589 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-07-29

No results posted yet for this study

Summary

The overall objectiv is to obtain preliminary evidence of efficacy of novel agents for the management of relapsed ovarian cancer, and in part 2 efficacy of novel agents compared to the standard of care (SoC).

Conditions

Interventions

DRUG

Durvalumab, Tremelilumab, MEDI 9447, MEDI 0562

Three different combination are being tested. Each cohort has different combination

Sponsors & Collaborators

  • Gynecologic Cancer Intergroup (GCIG)

    collaborator OTHER

  • European Network of Gynaecological Oncological Trial Groups (ENGOT)

    collaborator OTHER

  • Nordic Society of Gynaecological Oncology - Clinical Trials Unit

    lead OTHER

Principal Investigators

  • Mansoor R Mirza, MD · NSGO-CTU

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-14
Primary Completion
2021-10-19
Completion
2021-10-19

Countries

  • Denmark
  • Finland
  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03267589 on ClinicalTrials.gov